Form 4: NKGen Biotech CFO Granted 500,000 Stock Options

NKGen Biotech's Chief Financial Officer, James A. Graf, was granted 500,000 stock options under the company's 2023 Equity Incentive Plan.

Summary

• James A. Graf, the Chief Financial Officer of NKGen Biotech, Inc., received 500,000 stock options on December 6, 2024.
• These options were granted under the company's 2023 Equity Incentive Plan.
• 25% of the options vested immediately on the grant date.
• The remaining options will vest in 36 equal monthly installments, starting January 6, 2025, and ending December 6, 2027.
• Vesting is contingent upon Mr. Graf's continued employment with NKGen Biotech.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, indicating a positive but not exceptional event. The vesting schedule suggests a focus on long-term commitment.

Positives

• The grant of stock options aligns the CFO's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Risks

• The value of the options is dependent on the future performance of NKGen Biotech's stock price.
• If Mr. Graf leaves the company before all options vest, he will forfeit the unvested portion.

Future Outlook

The vesting of the stock options is contingent on the CFO's continued service with the company, suggesting a focus on long-term stability and performance.

Industry Context

Stock option grants are a common practice in the biotech industry to attract and retain key executives, aligning their interests with the company's long-term success.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, similar to companies like Amgen, Gilead Sciences, and Regeneron.
• The vesting schedule of 25% immediately and the remainder over three years is a typical structure for executive stock options.
• The number of options granted is likely based on the CFO's role, experience, and the company's overall compensation strategy, which is common practice across the industry.

Stakeholder Impact

• Shareholders may view this as a positive sign of aligning management's interests with the company's long-term performance.
• Employees may see this as a standard practice for executive compensation.

Key Dates

Keywords

stock options, equity incentive plan, vesting, CFO, NKGen Biotech, compensation